Inner Salt (e.g., Betaine, Etc.) Patents (Class 514/77)
-
Publication number: 20130337041Abstract: The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.Type: ApplicationFiled: February 25, 2013Publication date: December 19, 2013Applicants: Ottawa Heart Institute Research Corporation, Cerenis Therapeutics, S.A.Inventors: Cerenis Therapeutics, S.A., Ottawa Heart Institute Research Corporation
-
Publication number: 20130310339Abstract: A sexual function improving agent and the use thereof. Said sexual function improving agent comprises a phospholipid including a highly unsaturated fatty acid as a constituent fatty acid.Type: ApplicationFiled: February 1, 2012Publication date: November 21, 2013Applicant: NIPPON SUISAN KAISHA, LTD.Inventors: Li Han, Tomoko Tsuji, Pengtao Li, Jun Wang, Hongtao Lei
-
Publication number: 20130295203Abstract: Methods and compositions are disclosed to treat neuropsychiatric disorders based upon a new framework of diagnosis. Axis I biomarkers include genes related to prefrontal dopamine synthesis and/or dopamine degradation. Axis II includes genes related to re uptake of dopamine, norepinephrine and serotonin and autonomic hyperactivity. Axis III includes genes relates to impairments in inflammatory pathways, glutamate neurotransmission and/or neurotrophic factors. Axis IV includes genes related to glutamate reuptake and predisposition to addictive behavior, and obsessive compulsions.Type: ApplicationFiled: July 8, 2013Publication date: November 7, 2013Inventor: Jay L. LOMBARD
-
Publication number: 20130295171Abstract: A method of enhancing cardiovascular health includes administering a therapeutic amount of a composition comprising krill oil reacted with astaxanthin. A medicine delivery system for the method and composition includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S?-astaxanthin derived from Haematococcus pluvialis.Type: ApplicationFiled: July 9, 2013Publication date: November 7, 2013Inventors: John A. MINATELLI, W. Stephen Hill, Rudi E. Moerck
-
Publication number: 20130288956Abstract: An object of the present invention is to provide a pharmaceutical composition having superior antifungal activity. The present invention provides a pharmaceutical composition comprising 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine or 2-amino-1-((phosphonooxy)methyl)-3-(3-((4-((2-pyridinyloxy)methyl)phenyl)methyl)-5-isoxazolyl)-pyridinium or a salt thereof in combination with an antifungal agent.Type: ApplicationFiled: November 4, 2011Publication date: October 31, 2013Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Naoaki Watanabe, Katsura Hata, Mamiko Miyazaki, Takaaki Horii
-
Patent number: 8568771Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD1 33+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).Type: GrantFiled: October 29, 2007Date of Patent: October 29, 2013Assignee: Fresenius Medical Care Deutschland G.m.b.H.Inventors: Vincenzo Cantaluppi, Maria Chiara Deregibus, Giovanni Camussi
-
Publication number: 20130281405Abstract: Aerosolizable compositions of nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with zwitterionic phospholipids in an aqueous carrier are used for treating lung injury (LI), pulmonary inflammation, and/or airway hyper-responsiveness (AHR). Methods for administering the compositions including orally, parenterally, intra-tracheally, and intra-pulmonarily protocols, especially intra-tracheally and intra-pulmonarily protocols, where the PC-NSAID compositions reduce lung injury (LI), pulmonary inflammation, and/or airway hyper-responsiveness (AHR).Type: ApplicationFiled: April 2, 2013Publication date: October 24, 2013Inventors: Lenard M. Lichtenberger, Elizabeth J. Dial
-
Publication number: 20130281404Abstract: The present invention provides a method for producing a composition containing 2-acyl-lysophosphatidylserine, including (a) a step of obtaining a composition containing phosphatidylserine by allowing phospholipase D to act on a raw material containing phosphatidylcholine in the presence of serine and (b) a step of obtaining a composition containing 2-acyl-lysophosphatidylserine by allowing phospholipase A1 to act on the composition containing phosphatidylserine in the presence of one or more additives selected from the group consisting of the following (I), (II), and (III), in which (I) one or more salts selected from the group consisting of sulfate salts, phosphate salts, nitrate salts, citrate salts, and tartarate salts of monovalent cations, (II) a gum, and (III) an emulsifier.Type: ApplicationFiled: September 26, 2011Publication date: October 24, 2013Applicant: MEIJI CO., LTD.Inventors: Kazunaga Yazawa, Tomoyuki Susa, Shoji Gotoh, Yasuhito Tashiro, Junichi Kawashima, Shigeyuki Imamura
-
Publication number: 20130274228Abstract: The present invention aims to provide a medicament and/or food having a cognitive function improving effect, and a method of improving the cognitive function. The present invention relates to a concomitant drug for improving cognitive function, which contains 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, use of the concomitant drug for the improvement of learning and/or memory, a method for the improvement of cognitive function including administering the concomitant drug, and a method for the improvement of learning ability and/or memory ability including administering the concomitant drug.Type: ApplicationFiled: December 15, 2011Publication date: October 17, 2013Applicant: Nishizaki Bioinformation Research InstituteInventor: Tomoyuki Nishizaki
-
Patent number: 8557266Abstract: A synergistic antimicrobial composition comprising: (a) a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phoshponium salts and tris(hydroxymethyl)phosphine; and (b) tris(hydroxymethyl)nitromethane.Type: GrantFiled: June 17, 2010Date of Patent: October 15, 2013Assignee: Dow Global Technologies LLCInventor: Bei Yin
-
Publication number: 20130267480Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.Type: ApplicationFiled: May 24, 2013Publication date: October 10, 2013Inventors: Mahendra G. Dedhiya, Sisir Bhattacharya, Véronique Ducandas, Alexandre Giuliani, Valérie Ravaux, Alain Bonnet, Alain Priour, Peter Spargo
-
Patent number: 8551977Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolite antitumor substances for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or more antimetabolite antitumor substances. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.Type: GrantFiled: March 31, 2010Date of Patent: October 8, 2013Assignee: AEterna Zentaris GmbHInventors: Jurgen Engel, Eckhard Gunther, Herbert Sindermann
-
Publication number: 20130252923Abstract: A skin-beautifying agent, food, beverage, or feed for skin-beautification which has cosmetic effects such as moisturizing and beautifying the skin as well as preventing skin roughness and wrinkles by oral intake. Also described is a skin-beautifying agent containing a milk-derived phospholipid as an effective ingredient, and to provide food, beverage, or feed for skin- beautification containing the skin-beautifying agent. The milk-derived phospholipid is preferably a composition prepared from milk or milk material containing 40 to 70% by weight of lipid in a total solid content and containing 30% or more by weight of milk-derived phospholipid.Type: ApplicationFiled: May 15, 2013Publication date: September 26, 2013Applicant: MEGMILK SNOW BRAND CO., LTD.Inventors: Ken KATO, Yuko HARUTA, Tatsuya WATANABE, Hiroshi UENO, Noriko UEDA, Toshimitsu YOSHIOKA
-
Publication number: 20130244981Abstract: A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases.Type: ApplicationFiled: May 8, 2013Publication date: September 19, 2013Applicant: U.S. Nutraceuticals, LLC, d/b/a Valensa InternationalInventor: U.S. Nutraceuticals, LLC, d/b/a Valensa International
-
Publication number: 20130244962Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.Type: ApplicationFiled: April 11, 2013Publication date: September 19, 2013Applicant: Merck Frosst Canada Ltd.Inventors: Elise ISABEL, Christopher MELLON, Christian BEAULIEU
-
Publication number: 20130244982Abstract: Conjugates of drugs suitable for use in the treatment of inflammatory bowel disease and phospholipids, and their use in the treatment of inflammatory bowel disease, are disclosed. The disclosed conjugates serve as targeted prodrugs which are suitable for oral administration, and which are capable of releasing the drug selectively at the diseased tissue upon activation by PLA2.Type: ApplicationFiled: December 1, 2011Publication date: September 19, 2013Applicant: Bengurion University of the Negev Research and Development AuthorityInventor: Arik Dahan
-
Publication number: 20130231305Abstract: The present invention relates to a method of modulating cellular activity. More particularly, the present invention provides a method of modulating apoptosis by modulating protein 14-3-3 phosphorylation and, thereby its functionality. The present invention still further extends to methods for identifying agents capable of modulating protein 14-3-3 phosphorylation. The method and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted cellular activity, such as unwanted cell survival.Type: ApplicationFiled: March 29, 2011Publication date: September 5, 2013Applicant: Medvet Science Pty. Ltd.Inventors: Joanna Woodcock, Stuart Pitson, Angel Lopez
-
Publication number: 20130225526Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.Type: ApplicationFiled: April 15, 2013Publication date: August 29, 2013Applicant: MEGMILK SNOW BRAND CO., LTD.Inventor: MEGMILK SNOW BRAND CO., LTD.
-
Publication number: 20130225525Abstract: Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed.Type: ApplicationFiled: March 14, 2013Publication date: August 29, 2013Applicant: Vascular Biogenics Ltd.Inventor: Vascular Biogenics Ltd.
-
Patent number: 8507710Abstract: The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.Type: GrantFiled: March 31, 2010Date of Patent: August 13, 2013Assignee: AEterna Zentaris GmbHInventors: Jurgen Engel, Eckhard Gunther, Herbert Sindermann
-
Publication number: 20130184198Abstract: Synthetic pulmonary surfactant compositions comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid are provided. Methods for treating respiratory disease are also provided comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid.Type: ApplicationFiled: November 29, 2012Publication date: July 18, 2013Applicant: DISCOVERY LABORATORIES, INC.Inventor: Discovery Laboratories, Inc.
-
Patent number: 8486916Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.Type: GrantFiled: November 14, 2012Date of Patent: July 16, 2013Assignee: Megmilk Snow Brand Co., Ltd.Inventors: Ken Kato, Susumu Miura, Leo Tanaka, Hiroshi Ueno, Noriko Ueda, Yuko Haruta, Toshimitsu Yoshioka
-
Publication number: 20130172294Abstract: Unit dosage forms comprising between 1 mg and 100 mg VB-201 and a pharmaceutically acceptable carrier, and formulated for oral administration, are disclosed herein, as well as treatment regimens comprising oral administration of VB-201 once or twice daily for treating an inflammatory disease or disorder.Type: ApplicationFiled: January 5, 2011Publication date: July 4, 2013Applicant: Vascular Biogenics Ltd.Inventors: Yael Cohen, Naamit Sher, Itzhak Mendel, Niva Yacov, Eyal Breitbart
-
Patent number: 8470345Abstract: A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.Type: GrantFiled: November 16, 2009Date of Patent: June 25, 2013Assignee: Enzymotec Ltd.Inventors: Gai Ben Dror, Dorit Platt, Orly Farkash, Rassan Zuabi, Zohar Bar-On, Avidor Shulman, Dori Pelled
-
Publication number: 20130150327Abstract: There is provided a composition for preventing hair loss or stimulating hair growth, the composition including phospholipids as an effective component, and more preferably, a composition for preventing hair loss or stimulating hair growth, the composition including phospholipids that are extracted from animals as an effective component.Type: ApplicationFiled: May 17, 2011Publication date: June 13, 2013Applicant: Biopid CorporationInventor: Seong Hyun Choi
-
Publication number: 20130143842Abstract: Compositions containing one or more bioactive forms of creatine, which are aqueous compositions in which the one or more bioactive forms of creatine do not appreciably degrade into creatinine. Also are methods for providing various beneficial effects which comprise administering aqueous compositions comprising at least one creatinol O-phosphate species to a mammalian subject, either chronically or acutely.Type: ApplicationFiled: January 31, 2013Publication date: June 6, 2013Inventor: JOHN H. OWOC
-
Publication number: 20130121969Abstract: The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing with low heat generation to form materials suitable for use in scaffolds in tissue engineering applications such as bone and cartilage repair. The polymers are desirably flowable and injectable and can support living biological components to aid in the healing process. They may be cured ex-vivo for invasive surgical repair methods, or alternatively utilized for relatively non-invasive surgical repair methods such as by arthroscope. The invention also relates to prepolymers useful in the preparation of the polymeric compositions, and to methods of treatment of damaged tissue using the polymers of the invention.Type: ApplicationFiled: October 31, 2012Publication date: May 16, 2013Applicant: POLYNOVO BIOMATERIALS PTY LIMITEDInventors: Raju Adhikari, Pathiraja Arachchillage Gunatillake
-
Patent number: 8409550Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of at combination of retinoid boosters.Type: GrantFiled: June 21, 2012Date of Patent: April 2, 2013Assignee: Unilever Home & Personal Care, USA, Division of Conopco, Inc.Inventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Patent number: 8410085Abstract: We have discovered that phospholipids diundecanoyl (C11:0-C11:0) and dilauroyl (C12:0-C12:0) phosphatidylcholine (PC) act as agonists of the LRH-1 receptor. We have also shown that administration of these lipids to diabetic mice reduces blood glucose levels. On the basis of these discoveries, the present invention features compositions that include these lipids and structurally related lipids. Also featured are methods of treating metabolic disorders and inflammatory bowel disease, lowering blood glucose levels, and increasing LRH-1 receptor activity in a subject by administration of these lipids.Type: GrantFiled: November 17, 2008Date of Patent: April 2, 2013Assignee: Baylor College of MedicineInventors: David D. Moore, Jae Man Lee
-
Publication number: 20130079307Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.Type: ApplicationFiled: November 14, 2012Publication date: March 28, 2013Applicant: MEGMILK SNOW BRAND CO., LTD.Inventor: MEGMILK SNOW BRAND CO., LTD.
-
Patent number: 8394785Abstract: The present invention relates to a method for the treatment and/or amelioration of urticaria, the method comprising the administration of a pharmaceutically active dose of a compound of formula I to a subject in need of such a treatment and/or amelioration.Type: GrantFiled: July 6, 2011Date of Patent: March 12, 2013Assignee: Jado Technologies GmbHInventors: Tobias Braxmeier, Tim Friedrichson, Gary Jennings
-
Patent number: 8389497Abstract: The invention relates to the use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or a combination of various approved cytostatics. Preferred alkylphosphocholines are described by the Formula II.Type: GrantFiled: July 30, 2003Date of Patent: March 5, 2013Assignee: AEterna Zentaris GmbHInventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann
-
Patent number: 8383677Abstract: A nerve-regenerating agent comprising, as an active ingredient, arachidonic acid and/or a compound containing arachidonic acid as a constituent fatty acid.Type: GrantFiled: December 27, 2007Date of Patent: February 26, 2013Assignees: Suntory Holdings Limited, Tohoku UniversityInventors: Masanori Kontani, Yoshiyuki Ishikura, Noriko Oosumi, Motoko Maekawa
-
Patent number: 8383605Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.Type: GrantFiled: March 31, 2010Date of Patent: February 26, 2013Assignee: AEterna Zentaris GmbHInventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann, Babette Aicher
-
Publication number: 20130022687Abstract: The present invention proposes a cosmetic or pharmaceutical preparation that comprises a mixture of nutritional related co-factors synergistically combined and applied as a topical/transdermal surfactant. Said surfactant formula invokes a precise ordered and sequential synchrony within the treated area initiating the bodies' own natural biological and healing circadia. Said surfactant formula has the ability to regulate an inflammation response and infuse required nutrients for cellular repair at the treated area. The specific ingredients serve as a co-synergist for a clearly defined series of cascading biochemical loops that substantiate the use of each individual ingredient. The concert of regulation of an inflammation response coupled with infused nutritional co-factors and cascading biochemical loops yields a modulation of both chronic and acute inflammation or repair of injured tissue and joints as a result of injury, stress or disease.Type: ApplicationFiled: July 18, 2012Publication date: January 24, 2013Inventors: John James Fitzgerald, JR., Ranya Ludwig Alexander, Anthony Joseph Meduri
-
Publication number: 20130018012Abstract: The invention pertains to the use of a lipid fraction for the support of brain function. The lipid fraction comprises the medium-chain fatty acids at least 4 g hexanoic acid and/or at least 5 g octanoic acid, at least 1 g eicosapentaenoic acid, and in addition more than 0.4 g ?-linolenic acid per 100 g fatty acids of the lipid fraction.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Inventors: Robert Johan Joseph Hageman, Eline Marleen van der Beek, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Publication number: 20130018006Abstract: A group of compounds formed from phosphorylated monosaccharides and/or phosphorylated oligosaccharides esterified with physiologic methyl donors consisting of choline, and methyl donors chosen from a group consisting of esteried with a substance chosen from the group consisting of methylene choline and all their derivatives and metabolites thereof. A new compound, glycerylphosphorylcholine (GPC), and its use for slowing or reducing athersclerosis and arthritis, especially osteoarthritis. Several classes of agents to prevent and cure hardening of the arteries is described. The same physiologic interaction of calcium and phosphorus applies throughout. Additional components also make it effective against rheumatoid arthritis.Type: ApplicationFiled: April 5, 2012Publication date: January 17, 2013Inventor: Stephen King
-
Publication number: 20130011469Abstract: A medicine delivery system includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S?-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin. The medicine delivery system also includes 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule. In a specific example, the medicine delivery system includes about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule.Type: ApplicationFiled: July 19, 2012Publication date: January 10, 2013Applicant: U.S. Nutraceuticals, LLC d/b/a Valensa InternationalInventors: John A. MINATELLI, W. Stephen Hill, Rudi E. Moerck
-
Patent number: 8349902Abstract: The invention relates to pharmacology, medicine and oncology, in particular, to a class of chemical compounds, the structure of which corresponds to formula (I) and which can be used in pharmaceutical compositions for preventing and treating an extended range of oncological diseases, including, in the form of an anti-tumoral preparation and a preparation which is used for combined therapy of oncological diseases.Type: GrantFiled: January 29, 2007Date of Patent: January 8, 2013Assignee: Mitotech SAInventors: Vladimir P. Skulachev, Maxim V. Skulachev
-
Publication number: 20120328548Abstract: Provided are novel compositions exhibiting highly effective antiviral, antimicrobial and/or antifungal activity. The compositions of the invention can be used for sanitizing and/or disinfecting surfaces, e.g., inanimate and/or animate surfaces. Preferred compositions include a synergistic combination of an alcohol, docusate, geraniol and, optionally, menthol. The invention provides compositions that have high antimicrobial activity, yet are mild, non-irritating, quick drying, non-sticky and not drying to the skin. Processes for manufacturing and using the compositions and products containing such compositions are also disclosed.Type: ApplicationFiled: October 1, 2010Publication date: December 27, 2012Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventor: Elka Touitou
-
Publication number: 20120329737Abstract: The invention relates to hybrid molecules made of two lipids or lipid-analogous compounds which are linked to each other via their lipophilic end. The hybrid molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the hybrid molecule. The hybrid molecules according to the invention can be used as pharmaceutical or as a cosmetic preparation.Type: ApplicationFiled: June 23, 2010Publication date: December 27, 2012Inventor: Hans-Uwe Wolf
-
Publication number: 20120329758Abstract: Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed.Type: ApplicationFiled: January 5, 2011Publication date: December 27, 2012Inventors: Yael Cohen, Niva Yacov, Eyal Breitbart
-
Publication number: 20120329757Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: ApplicationFiled: March 27, 2012Publication date: December 27, 2012Inventors: Dror HARATS, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Publication number: 20120321602Abstract: A novel omega-3 fatty acid/lipid based nutraceutical composition and a method of optimizing said omega-3 fatty acid/lipid based nutraceutical composition. The nutraceutical composition and method is based on the insight that different forms of high omega-3 fatty acid lipids (e.g. triglyceride form, ethyl ester form, free fatty acid form, phospholipid form) have different molecular modes and levels of action. Specifically the phospholipid form is likely more effective at promoting membrane fluidity and permeability, while the free fatty acid form is likely more effective at regulating cell receptors, such as the PPAR? receptors, that are responsible for various metabolic effects including lipid metabolism. The desirability of producing omega-3 compositions that may act synergistically and thus more robustly to improve health and to some extent mimic markers of life extension such as shown by caloric restriction, along with specific optimization methods, markers, and compositions are taught.Type: ApplicationFiled: June 15, 2011Publication date: December 20, 2012Inventor: Ronald E. Rosedale
-
Publication number: 20120315298Abstract: A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.Type: ApplicationFiled: June 15, 2012Publication date: December 13, 2012Applicant: NEXGENIX PHARMACEUTICALS, INCInventors: Ruihong CHEN, Allan E. Rubenstein, Xiaodong Shen, Scott Stewart, Jin-Chen Yu
-
Publication number: 20120309716Abstract: Provided are a motor function improver, an endurance improver, a muscle strength improver, a muscle strength deterioration suppressor, an anti-fatigue agent, a mitochondrial function improver, an energy consumption promoter, and a lipid combustion promoter which contain a sphingomyelin as an active ingredient.Type: ApplicationFiled: February 2, 2011Publication date: December 6, 2012Applicant: Kao CorporationInventors: Satoshi Haramizu, Noriyasu Ota, Kohjiro Hashizume, Takatoshi Murase
-
Patent number: 8324188Abstract: A method to determine the utility of small molecules as functional replacements (mimetics) for protein receptor ligands is described. The method uses cellular biological assays on a systematic array of compounds, comprising known protein receptor ligands and other biologically active molecules to determine if a proposed small molecule is a functional equivalent of a receptor ligand, having therapeutic utility as a pharmaceutically relevant and useful agent either alone or in combination with other molecules. Furthermore, the invention provides for a method for the treatment of cancer comprising administering a combination of ET-18-O-CH3 and an anti-cancer agent.Type: GrantFiled: November 9, 2007Date of Patent: December 4, 2012Inventors: Vladimir Khazak, Lutz Weber
-
Publication number: 20120302518Abstract: Disclosed herein, in certain embodiments, is a crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. Further disclosed herein, in certain embodiments, are pharmaceutical compositions comprising the crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.Type: ApplicationFiled: July 24, 2012Publication date: November 29, 2012Applicant: ARDEA BIOSCIENCES, INC.Inventor: Stuart DIMOCK
-
Publication number: 20120277187Abstract: An agent for preventing an infection with an influenza virus or a food or drink for preventing infection with an influenza virus is provided. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which comprises a fat globule membrane component as an active ingredient. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which comprises a sphigosine-containing phospholipid and/or a derivative thereof, particularly sphingomyelin, as an active ingredient.Type: ApplicationFiled: July 9, 2012Publication date: November 1, 2012Inventor: Hiroshi Kawakami
-
Publication number: 20120264703Abstract: The present invention provides novel methods and formulations for treating anxiety disorders, including Post Traumatic Stress Disorder, in human subjects employing coordinate treatment using ? and ? blockers alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce symptomology in treated subjects.Type: ApplicationFiled: June 15, 2012Publication date: October 18, 2012Inventors: Arifulla Khan, John Frederick Reinhard, JR.